Avidity Biosciences (RNA) News Today $33.13 +0.39 (+1.19%) (As of 12:58 PM ET) Add Compare Share Share Headlines Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipShort InterestTrends All Sources Trusted Sources MarketBeat Benzinga Bloomberg GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha TalkMarkets The Street TipRanks The Wall Street Journal Wall Street Zen Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent December 2024 November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 August 2022 July 2022 June 2022 May 2022 April 2022 March 2022 February 2022 January 2022 Time Period Geode Capital Management LLC Has $118.77 Million Stake in Avidity Biosciences, Inc. (NASDAQ:RNA)Geode Capital Management LLC raised its stake in shares of Avidity Biosciences, Inc. (NASDAQ:RNA - Free Report) by 14.6% in the 3rd quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The firm owned 2,585,303 shares of the biotechnology company's stock afteDecember 18 at 4:17 AM | marketbeat.comAvidity Biosciences (NASDAQ:RNA) Shares Gap Down - Here's What HappenedAvidity Biosciences (NASDAQ:RNA) Shares Gap Down - Should You Sell?December 17 at 1:27 PM | marketbeat.comBarclays PLC Has $11.74 Million Stake in Avidity Biosciences, Inc. (NASDAQ:RNA)Barclays PLC boosted its stake in Avidity Biosciences, Inc. (NASDAQ:RNA - Free Report) by 68.5% in the third quarter, according to its most recent disclosure with the Securities and Exchange Commission. The fund owned 255,699 shares of the biotechnology company's stock after purchasing an additionaDecember 17 at 4:02 AM | marketbeat.comAvidity Biosciences, Inc. (NASDAQ:RNA) Shares Purchased by Lord Abbett & CO. LLCLord Abbett & CO. LLC increased its stake in Avidity Biosciences, Inc. (NASDAQ:RNA - Free Report) by 30.1% in the third quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The institutional investor owned 539,207 shares of the biotechnology company's stoDecember 16 at 5:39 AM | marketbeat.comW. Michael Flanagan Sells 24,000 Shares of Avidity Biosciences, Inc. (NASDAQ:RNA) StockDecember 14, 2024 | insidertrades.comAvidity Biosciences, Inc. (NASDAQ:RNA) Insider Sells $858,480.00 in StockAvidity Biosciences, Inc. (NASDAQ:RNA - Get Free Report) insider W. Michael Flanagan sold 24,000 shares of the firm's stock in a transaction that occurred on Wednesday, December 11th. The stock was sold at an average price of $35.77, for a total transaction of $858,480.00. Following the sale, the insider now owns 85,389 shares of the company's stock, valued at approximately $3,054,364.53. This represents a 21.94 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which can be accessed through this link.December 13, 2024 | marketbeat.comAvidity Biosciences (RNA) Receives a Buy from TD CowenDecember 13, 2024 | markets.businessinsider.comBrokerages Set Avidity Biosciences, Inc. (NASDAQ:RNA) PT at $63.60December 13, 2024 | americanbankingnews.comNeo Ivy Capital Management Invests $762,000 in Avidity Biosciences, Inc. (NASDAQ:RNA)Neo Ivy Capital Management bought a new stake in Avidity Biosciences, Inc. (NASDAQ:RNA - Free Report) during the third quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm bought 16,596 shares of the biotechnology company's stock, valued at apDecember 12, 2024 | marketbeat.comState Street Corp Purchases 1,386,087 Shares of Avidity Biosciences, Inc. (NASDAQ:RNA)State Street Corp increased its position in Avidity Biosciences, Inc. (NASDAQ:RNA - Free Report) by 41.7% during the third quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 4,706,106 shares of the biotechDecember 12, 2024 | marketbeat.comAvidity Biosciences Advances With FDA Clearance And Promising Data For Rare DiseasesDecember 11, 2024 | seekingalpha.comAvidity Biosciences (NASDAQ:RNA) Stock Quotes, Forecast and News SummaryDecember 11, 2024 | benzinga.comCastleark Management LLC Acquires New Holdings in Avidity Biosciences, Inc. (NASDAQ:RNA)Castleark Management LLC bought a new position in Avidity Biosciences, Inc. (NASDAQ:RNA - Free Report) in the third quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund bought 57,110 shares of the biotechnology company's stock, valued at approximaDecember 8, 2024 | marketbeat.comWellington Management Group LLP Acquires 3,228,923 Shares of Avidity Biosciences, Inc. (NASDAQ:RNA)Wellington Management Group LLP lifted its position in Avidity Biosciences, Inc. (NASDAQ:RNA - Free Report) by 84.9% in the third quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 7,030,949 shares of the biotechnology company's stock aDecember 8, 2024 | marketbeat.comAvidity Biosciences, Inc. (NASDAQ:RNA) Receives Consensus Recommendation of "Buy" from AnalystsShares of Avidity Biosciences, Inc. (NASDAQ:RNA - Get Free Report) have earned an average recommendation of "Buy" from the ten ratings firms that are covering the firm, Marketbeat Ratings reports. Ten investment analysts have rated the stock with a buy recommendation. The average 1-year price objeDecember 8, 2024 | marketbeat.comAvidity Biosciences, Inc. (NASDAQ:RNA) Shares Acquired by RA Capital Management L.P.RA Capital Management L.P. grew its holdings in Avidity Biosciences, Inc. (NASDAQ:RNA - Free Report) by 16.7% in the 3rd quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 6,300,408 shares of the biotDecember 5, 2024 | marketbeat.comAvidity Biosciences, Inc. (NASDAQ:RNA) is RTW Investments LP's 3rd Largest PositionRTW Investments LP lowered its position in shares of Avidity Biosciences, Inc. (NASDAQ:RNA - Free Report) by 7.7% in the third quarter, according to the company in its most recent 13F filing with the SEC. The fund owned 8,132,870 shares of the biotechnology company's stock after selling 673,968 shaDecember 5, 2024 | marketbeat.comAvidity Biosciences, Inc. (NASDAQ:RNA) Shares Bought by Janus Henderson Group PLCJanus Henderson Group PLC grew its stake in shares of Avidity Biosciences, Inc. (NASDAQ:RNA - Free Report) by 33.9% in the 3rd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 4,896,166 shares of the biotechnology company's stock afteDecember 4, 2024 | marketbeat.comCinctive Capital Management LP Trims Position in Avidity Biosciences, Inc. (NASDAQ:RNA)Cinctive Capital Management LP reduced its position in shares of Avidity Biosciences, Inc. (NASDAQ:RNA - Free Report) by 43.0% in the 3rd quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The fund owned 47,554 shares of the biotechnology coDecember 3, 2024 | marketbeat.comThe Manufacturers Life Insurance Company Lowers Stake in Avidity Biosciences, Inc. (NASDAQ:RNA)The Manufacturers Life Insurance Company lessened its holdings in Avidity Biosciences, Inc. (NASDAQ:RNA - Free Report) by 5.6% during the third quarter, according to the company in its most recent disclosure with the SEC. The firm owned 257,456 shares of the biotechnology company's stock after sellDecember 3, 2024 | marketbeat.comCharles Schwab Investment Management Inc. Purchases 197,065 Shares of Avidity Biosciences, Inc. (NASDAQ:RNA)Charles Schwab Investment Management Inc. raised its holdings in Avidity Biosciences, Inc. (NASDAQ:RNA - Free Report) by 24.8% during the 3rd quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 990,182 shares of the biotechnology company'sDecember 2, 2024 | marketbeat.comAlethea Capital Management LLC Reduces Holdings in Avidity Biosciences, Inc. (NASDAQ:RNA)Alethea Capital Management LLC cut its position in Avidity Biosciences, Inc. (NASDAQ:RNA - Free Report) by 15.1% during the 3rd quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 427,454 shares of the biotechnologyDecember 1, 2024 | marketbeat.comFmr LLC Acquires 689,729 Shares of Avidity Biosciences, Inc. (NASDAQ:RNA)Fmr LLC boosted its holdings in shares of Avidity Biosciences, Inc. (NASDAQ:RNA - Free Report) by 4.3% in the 3rd quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The firm owned 16,848,776 shares of the biotechnology company's stock afteNovember 28, 2024 | marketbeat.comAvidity Biosciences: Advancing Clinical Programs with Strategic Focus and Growth PotentialNovember 27, 2024 | markets.businessinsider.comAvidity Biosciences initiated with an Outperform at RBC CapitalNovember 27, 2024 | markets.businessinsider.comRBC Capital Initiates Coverage of Avidity Biosciences (RNA) with Outperform RecommendationNovember 26, 2024 | msn.comAvidity Biosciences to Participate in Upcoming Investor ConferenceNovember 26, 2024 | prnewswire.comRoyal Bank of Canada Begins Coverage on Avidity Biosciences (NASDAQ:RNA)Royal Bank of Canada assumed coverage on shares of Avidity Biosciences in a research report on Tuesday. They issued an "outperform" rating and a $67.00 target price on the stock.November 26, 2024 | marketbeat.comIntech Investment Management LLC Makes New Investment in Avidity Biosciences, Inc. (NASDAQ:RNA)Intech Investment Management LLC purchased a new position in Avidity Biosciences, Inc. (NASDAQ:RNA - Free Report) during the 3rd quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor purchased 37,036 shares of theNovember 26, 2024 | marketbeat.comVictory Capital Management Inc. Purchases 11,367 Shares of Avidity Biosciences, Inc. (NASDAQ:RNA)Victory Capital Management Inc. raised its holdings in shares of Avidity Biosciences, Inc. (NASDAQ:RNA - Free Report) by 52.1% during the third quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 33,184 shares of the biotechnNovember 26, 2024 | marketbeat.comConnor Clark & Lunn Investment Management Ltd. Has $9.97 Million Position in Avidity Biosciences, Inc. (NASDAQ:RNA)Connor Clark & Lunn Investment Management Ltd. grew its holdings in Avidity Biosciences, Inc. (NASDAQ:RNA - Free Report) by 3,836.6% in the third quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor owned 217,025 shares of the biotechnology compaNovember 22, 2024 | marketbeat.comAvidity Biosciences Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)November 21, 2024 | prnewswire.comAvidity Biosciences, Inc. (NASDAQ:RNA) Director Arthur A. Levin Sells 3,323 SharesNovember 21, 2024 | insidertrades.comMutual of America Capital Management LLC Cuts Stock Holdings in Avidity Biosciences, Inc. (NASDAQ:RNA)Mutual of America Capital Management LLC reduced its stake in Avidity Biosciences, Inc. (NASDAQ:RNA - Free Report) by 10.4% during the 3rd quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 164,997 sharNovember 19, 2024 | marketbeat.comFY2024 EPS Estimates for RNA Decreased by Cantor FitzgeraldAvidity Biosciences, Inc. (NASDAQ:RNA - Free Report) - Research analysts at Cantor Fitzgerald cut their FY2024 earnings per share (EPS) estimates for Avidity Biosciences in a report released on Wednesday, November 13th. Cantor Fitzgerald analyst E. Schmidt now expects that the biotechnology compaNovember 18, 2024 | marketbeat.comLos Angeles Capital Management LLC Takes Position in Avidity Biosciences, Inc. (NASDAQ:RNA)Los Angeles Capital Management LLC bought a new stake in Avidity Biosciences, Inc. (NASDAQ:RNA - Free Report) during the third quarter, according to its most recent disclosure with the Securities and Exchange Commission. The fund bought 14,376 shares of the biotechnology company's stock, valued atNovember 17, 2024 | marketbeat.com44,898 Shares in Avidity Biosciences, Inc. (NASDAQ:RNA) Bought by State of New Jersey Common Pension Fund DState of New Jersey Common Pension Fund D bought a new stake in Avidity Biosciences, Inc. (NASDAQ:RNA - Free Report) during the 3rd quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor bought 44,898 shares ofNovember 16, 2024 | marketbeat.comAssetmark Inc. Invests $566,000 in Avidity Biosciences, Inc. (NASDAQ:RNA)Assetmark Inc. bought a new position in Avidity Biosciences, Inc. (NASDAQ:RNA - Free Report) during the 3rd quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The firm bought 12,319 shares of the biotechnology company's stock, valued at apNovember 16, 2024 | marketbeat.comAvidity Biosciences (NASDAQ:RNA) Stock Price Down 7.8% - Here's WhyAvidity Biosciences (NASDAQ:RNA) Stock Price Down 7.8% - What's Next?November 15, 2024 | marketbeat.comUS Bancorp DE Cuts Stock Position in Avidity Biosciences, Inc. (NASDAQ:RNA)US Bancorp DE trimmed its position in shares of Avidity Biosciences, Inc. (NASDAQ:RNA - Free Report) by 91.0% during the third quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The institutional investor owned 5,244 shares of the biotechnologyNovember 14, 2024 | marketbeat.comAvidity Biosciences’ Strategic Expansion in Precision Cardiology and siRNA Innovation Justifies Buy RatingNovember 13, 2024 | markets.businessinsider.comAssessing Avidity Biosciences: Insights From 10 Financial AnalystsNovember 13, 2024 | benzinga.comAvidity Bio Has Surged 416% This Year — And That's Before Today's 'Game-Changing' NewsNovember 13, 2024 | msn.comAvidity Biosciences jumps 16%; reaches all-time highNovember 13, 2024 | seekingalpha.comAvidity Biosciences (RNA) Gets a Buy from BarclaysNovember 13, 2024 | markets.businessinsider.comAvidity Bio Has Surged 416% This Year — And That's Before Today's 'Game-Changing' NewsNovember 13, 2024 | investors.comAvidity Biosciences (NASDAQ:RNA) Hits New 52-Week High - Should You Buy?Avidity Biosciences (NASDAQ:RNA) Reaches New 1-Year High - Still a Buy?November 13, 2024 | marketbeat.comNeedham & Company LLC Reaffirms "Buy" Rating for Avidity Biosciences (NASDAQ:RNA)Needham & Company LLC reaffirmed a "buy" rating and issued a $60.00 price target on shares of Avidity Biosciences in a research note on Wednesday.November 13, 2024 | marketbeat.comPromising Outlook for Avidity Biosciences: Strategic Focus on Genetic Targeting and Innovative AOC TechnologyNovember 13, 2024 | markets.businessinsider.comAvidity Biosciences, Inc. (NASDAQ:RNA) Receives Average Rating of "Buy" from AnalystsShares of Avidity Biosciences, Inc. (NASDAQ:RNA - Get Free Report) have received an average recommendation of "Buy" from the nine ratings firms that are currently covering the company, Marketbeat reports. Nine investment analysts have rated the stock with a buy recommendation. The average 12-monthNovember 13, 2024 | marketbeat.com Get Avidity Biosciences News Delivered to You Automatically Sign up to receive the latest news and ratings for RNA and its competitors with MarketBeat's FREE daily newsletter. Email Address Do this Before Elon’s Reveal on January 22nd (Ad)Elon’s newest tech could pay you an extra $30,000 a year — while you sleep. It’s smaller than a quarter but designed to power a $9 trillion AI revolution. And I’ve identified a little-known supplier Elon is depending on to make it all happen. I urge you to watch this video now. RNA Media Mentions By Week RNA Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. RNA News Sentiment▼0.850.55▲Average Medical News Sentiment RNA News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. RNA Articles This Week▼116▲RNA Articles Average Week Get Avidity Biosciences News Delivered to You Automatically Sign up to receive the latest news and ratings for RNA and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies Moderna News Today Viatris News Today Summit Therapeutics News Today Genmab A/S News Today Dr. Reddy's Laboratories News Today Sarepta Therapeutics News Today Catalent News Today Vaxcyte News Today Qiagen News Today Intra-Cellular Therapies News Today Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:RNA) was last updated on 12/18/2024 by MarketBeat.com Staff From Our PartnersThis drone stock is setting up to transform medical supply deliveryDrone stocks are on a tear, with certain symbols seeing gains as high as 300% over just a matter of weeks.The Tomorrow Investor | SponsoredHealthcare Takes A Big Step Forward With The Help of A.I.To date, we've seen baseline AI models lay the groundwork. Tools like ChatGPT are useful, but they are still s...Wall Street Star | Sponsored Is Starlink Set For The Largest IPO In History?He turned PayPal from a tiny, off-the-radar startup… to a massive $64 billion giant. Then, he did it again ...Paradigm Press | SponsoredUncover the Top Gold Stock of the Bull MarketGold Stocks Are Surging—Is West Red Lake Gold Mines Your Next Profit Play?Huge Alerts | SponsoredURGENT: This Altcoin Opportunity Won’t Wait – Act NowIt’s here. This is the moment we’ve been waiting for. The next 3-6 months in crypto will be absolutely life...Crypto Swap Profits | SponsoredDeFi Coin on Verge of Breakout!The blueprint for millionaires is here. Don't let this be the missed opportunity you regret for years. Crypto 101 Media | SponsoredSeeing is believing… Today, I want to share all the details with you… and show you how to leverage this incredible wealth-building ...Porter & Company | SponsoredPlease don’t take this warning lightly…Something huge is about to hit the stock market. Wall St. legend Louis Navellier calls it: "The most signif...InvestorPlace | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Avidity Biosciences, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Avidity Biosciences With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free RNA Stock Alerts